Kellogg is the exclusive site for the first human trial of a transplant of retinal pigment epithelium (RPE) cells generated from human donor RPE stem cells.
The new Vision Rehabilitation Section expands services to those with compromised peripheral vision and other conditions such as traumatic brain injury.
